PMID- 31955630
OWN - NLM
STAT- MEDLINE
DCOM- 20210322
LR  - 20210322
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 36
IP  - 4
DP  - 2020 Apr
TI  - Efficacy and safety of amlodipine/valsartan/hydrochlorothiazide single pill 
      combination in Egyptian patients with hypertension uncontrolled on any dual 
      therapy: an observational study.
PG  - 537-544
LID - 10.1080/03007995.2020.1719394 [doi]
AB  - Objective: Hypertension is a serious health problem in Egypt, with prevalence 
      rate of 17% as reported in 2015. Despite receiving treatment, many do not achieve 
      blood pressure (BP) control. The current study aimed to evaluate the efficacy and 
      tolerability of amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) single 
      pill combination (SPC) in patients with hypertension from Egypt, who were 
      uncontrolled on any dual therapy.Methods: In this prospective, open label, 
      multicenter, 12-week observational, cohort study, two doses of Aml/Val/HCTZ 
      (5/160/12.5 mg or 10/160/25 mg) SPC were used to evaluate mean change in BP after 
      12 weeks (primary endpoint). Safety assessments included presence and intensity 
      of ankle edema and other adverse events (AEs).Results: Data were collected from 
      1080 patients who were treated according to the routine medical practice across 
      47 centers in Egypt. Significant reduction in systolic and diastolic BP (SBP/DBP) 
      was observed from 165.5 +/- 12.83/100.8 +/- 7.03 mmHg at baseline to 
      129.7 +/- 8.35/80.6 +/- 5.25 mmHg after 12 weeks of treatment (p < .0001). Majority 
      of patients (76.85%) reached the BP goal of <140/90 mmHg. The most commonly 
      reported AE was ankle edema (10.92%).Conclusions: Aml/Val/HCT SPC significantly 
      reduced BP and was well tolerated in Egyptian patients with hypertension not 
      controlled on any previous dual therapy.
FAU - El-Etriby, Adel Mohamed Kamal
AU  - El-Etriby AMK
AD  - Faculty of Medicine, Ain Shams University, Cairo, Egypt.
FAU - Rakha, Sameh
AU  - Rakha S
AD  - Novartis Pharma S.A.E., Cairo, Egypt.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200204
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Amlodipine, Valsartan Drug Combination)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Drug Combinations)
RN  - 0J48LPH2TH (Hydrochlorothiazide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Amlodipine, Valsartan Drug Combination/*administration & dosage/adverse effects
MH  - Antihypertensive Agents/*therapeutic use
MH  - Drug Combinations
MH  - Edema/chemically induced
MH  - Female
MH  - Humans
MH  - Hydrochlorothiazide/*administration & dosage
MH  - Hypertension/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
OTO - NOTNLM
OT  - Compliance
OT  - Egypt
OT  - efficacy
OT  - hypertension
OT  - safety
OT  - triple therapy
EDAT- 2020/01/21 06:00
MHDA- 2021/03/23 06:00
CRDT- 2020/01/21 06:00
PHST- 2020/01/21 06:00 [pubmed]
PHST- 2021/03/23 06:00 [medline]
PHST- 2020/01/21 06:00 [entrez]
AID - 10.1080/03007995.2020.1719394 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2020 Apr;36(4):537-544. doi: 10.1080/03007995.2020.1719394. 
      Epub 2020 Feb 4.